Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
about
Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis CHepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a ReinfectionDesirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We NeedValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceThe Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current ChallengesWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataDrug Pricing Evolution in Hepatitis CCharacterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisTreatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis CImmunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virusLimiting the access to direct-acting antivirals against HCV: an ethical dilemma.Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States.Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients.Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaEvaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C VirusDecreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.Why We Should Be Willing to Pay for Hepatitis C Treatment.Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Suppression of Drug Resistance in Dengue Virus.Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulationThe Impact of Enhanced Screening and Treatment on Hepatitis C in the United StatesPricey pills for an even pricier problem.Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studiesPrevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesChronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino VeteransEconomic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.Cost-effectiveness thresholds: pros and cons.Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.
P2860
Q26774517-2D6910FC-05FC-4329-9633-248405D83620Q26801828-41E12E33-4951-4BB2-8EBF-068830F4A03EQ27468931-F21C38AA-810F-4CA5-9FF2-23634572E489Q28067411-AB21BDC9-A9C3-4A9A-B3F8-8BF5FD833DA3Q28072257-199E03E3-B735-4F8A-8C28-1A0212D0CD05Q28081108-14FDF3B8-8BA6-40A3-B6A0-B91633522944Q28550101-495234D8-79A3-4ECB-ABAF-3746FE871E74Q28550311-BD92972A-F11A-49C4-BC2B-C800C1C28D78Q28551538-F6ECABA8-4C2D-40FD-AB94-C556E0E83EE9Q28552507-8AAB46E6-8650-4B4C-A4A5-0226E183777FQ28552691-6399C562-77AD-4144-96C2-08ED7E924997Q28604286-3265E879-9A14-431C-AD7D-51685F20B2DFQ30244361-0617EE12-18DC-4872-BE54-F2104149ED3AQ30376341-B0C1C374-851C-4D4B-B464-9906B01E6CC4Q30746254-50E74A3F-AA2B-4136-82EA-E746982A39DCQ33435950-98B2D8FA-23A9-4D61-9986-E8380E944A8CQ33621614-A5BDCB9B-08A8-46A3-916E-E9F95881CAFFQ33629561-2346A7B3-C6F1-4DA5-91EE-8EF514DF9625Q33652027-3341A852-7B99-4A15-8E75-CEEEE772456CQ33698956-12D83887-68E1-47D7-95CC-C1957E646B44Q33879348-2BC08D96-4010-479D-AF00-BDE36BFFD131Q35922068-71F34CC9-A690-4E0D-8374-916F7E19DCF7Q36075161-3C9CDA3B-FB2C-4A2D-A80F-D4F7A445F6B5Q36238515-D9DA9779-D3C3-4844-A211-A86BF3467B6BQ36257494-A52B1594-D02C-4E3C-835B-E3231D9DBE0DQ36336005-5703C481-CAD2-4FF7-9798-82BD36C5E84BQ36431588-CE76CF2F-61A8-469C-8A9C-2255CFEF92FAQ36444618-3D1A3C7E-7322-4386-8DD6-57C3A8AE6A17Q36446133-F9EBC0F6-33B2-4020-948D-BA67F72AD8E0Q36751083-9399809C-4000-4701-B73B-B8095CD4EBB8Q36761430-3D341F31-DC5F-4213-9D75-CB87C9820020Q36862066-3A342BAE-08A1-41D6-A41B-853EA17CFF0FQ37018850-00D91BD6-BD8E-4B18-BB4A-0A821A3FE2D8Q37021497-2DD312D2-F856-4974-B604-9F82CF2AFFC5Q37027342-43D9CCC4-E3A5-4A4E-8700-D39E59A5A76CQ37137944-DF9A62CF-7FC5-4411-ACC7-B4F5BF2C790DQ37484155-EC7AFD51-78FA-442D-86CB-4B69317FBC1CQ37498173-8D0D15C2-5F83-4F40-B5D8-25A00B465FF8Q37555115-0B419C53-633D-47AB-AA96-2BCB3F761CA1Q37578288-C6D255EB-3E66-4D88-9C07-945BAC96A913
P2860
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness and budget ...... edipasvir in the United States
@ast
Cost-effectiveness and budget ...... edipasvir in the United States
@en
type
label
Cost-effectiveness and budget ...... edipasvir in the United States
@ast
Cost-effectiveness and budget ...... edipasvir in the United States
@en
prefLabel
Cost-effectiveness and budget ...... edipasvir in the United States
@ast
Cost-effectiveness and budget ...... edipasvir in the United States
@en
P2093
P2860
P356
P1476
Cost-effectiveness and budget ...... edipasvir in the United States
@en
P2093
Fasiha Kanwal
Jagpreet Chhatwal
Mark S Roberts
Michael A Dunn
P2860
P304
P356
10.7326/M14-1336
P407
P577
2015-03-01T00:00:00Z